NOE Landesgesundheitsagentur

At NOE Landesgesundheitsagentur in Mistelbach, the clinical research program in cardiovascular diseases focuses on major conditions such as acute ischemic stroke, high-risk transient ischemic attack, atrial fibrillation, acute myocardial infarction, and broader atherosclerotic cardiovascular disease. The trials are designed to test new treatment options, reduce stroke and bleeding risk, and improve long-term prevention for people at elevated cardiovascular risk.

• Evaluating therapies aimed at lowering the risk of ischemic stroke and systemic embolism
• Studying safer and more effective prevention strategies in atrial fibrillation
• Assessing approaches to better manage recurrent cardiovascular events and elevated lipoprotein(a)

This area brings together prevention, treatment effectiveness, and risk reduction research for patients with serious heart and vascular conditions.

The site also contributes to research in eye diseases, with a strong focus on neovascular age-related macular degeneration. These studies aim to improve vision outcomes, reduce treatment burden, and explore more durable ways to control retinal disease activity in adults affected by this leading cause of vision loss.

• Testing longer-lasting treatment approaches for nAMD
• Measuring how well new retinal therapies preserve visual acuity over time
• Comparing treatment burden and effectiveness against standard eye care

The research reflects a practical goal: maintaining sight while making care easier and more sustainable for patients.

In neoplasms, the clinical trials at this hospital include work in early breast cancer, especially hormone receptor-positive, HER2-negative disease. The main purpose is to determine whether adding a new therapy to standard endocrine treatment can improve outcomes and lower the chance of disease recurrence.

• Studying whether treatment intensification can improve invasive disease-free survival
• Supporting better long-term outcomes in breast cancer
• Exploring more effective options alongside established endocrine therapy

This oncology research is centered on strengthening standard care for patients with early-stage cancer while keeping treatment decisions grounded in measurable benefit.